St. Jude Medical Sees Revenue Falling Short of Views--Update
January 13 2016 - 12:28PM
Dow Jones News
By Lisa Beilfuss
Device maker St. Jude Medical Inc. said fourth-quarter earnings
would match expectations, though revenue would fall slightly short
amid weakness in its cardiac rhythm segment.
The St. Paul, Minn., company bumped up the low end of its
forecast for adjusted per-share profit, after cutting its guidance
in October, now expecting $1.01 to $1.02 a share for the December
quarter. Analysts have predicted $1.01 a share.
Revenue, St. Jude said, would come in at about $1.45 billion,
shy of the $1.48 billion analysts have projected.
"The pressures to our business that we communicated heading into
the quarter were partially offset by continued growth in atrial
fibrillation and neuromodulation as well as strong sales from the
recent Thoratec acquisition," Chief Executive Michael Rousseau
said.
St. Jude shares fell 3% to $57.40 in midday trading in New
York.
Sales in the company's cardiac rhythm segment--its biggest
business and maker of pacemakers, among other products--fell a
currency-adjusted 10% during the quarter, pressuring the top line,
as St. Jude faces rising pressure in its MRI conditional category
of products. That decline was countered by increases elsewhere:
Atrial fibrillation sales rose 4%, cardiovascular revenue inched up
2% and sales of neuromodulation products grew 9%.
Thoratec product sales were $136 million during the period,
above the $125 million to $130 million St. Jude had anticipated.
The company in October bought heart-device maker Thoratec Corp. for
about $3.4 billion, a move to beef up its presence in the market
for heart failure therapies.
St. Jude will report full fourth-quarter results on Jan. 27.
Write to Lisa Beilfuss at lisa.beilfuss@wsj.com
(END) Dow Jones Newswires
January 13, 2016 13:13 ET (18:13 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
SJM (NYSE:STJ)
Historical Stock Chart
From Apr 2024 to May 2024
SJM (NYSE:STJ)
Historical Stock Chart
From May 2023 to May 2024